(Q73850243)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837564%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837564%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

1 reference

Okada H

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837564%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 October 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837564%20AND%20SRC:MED&resulttype=core&format=json

Advanced Drug Delivery Reviews

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837564%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837564%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837564%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

43-70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837564%20AND%20SRC:MED&resulttype=core&format=json

Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10.

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men**Supported in part by the National Cancer Institute of Canada; Hoechst AG, Frankf

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats II: mechanism of absorption enhancement with organic acids.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats III: Effect of estrous cycle on vaginal absorption of hydrophilic model compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Desensitization of gonadotropin-releasing response following vaginal consecutive administration of leuprolide in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Once-a-Month Injectable Microcapsules of Leuprorelin Acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Biodegradable microspheres in drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Persistent suppression of the pituitary-gonadal system in female rats by three-month depot injectable microspheres of leuprorelin acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Interim report of a large French multicentre study of efficacy and safety of 3.75 mg leuprorelin depot in metastatic prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Leuprorelin acetate depot: results of a multicentre Japanese trial. TAP-144-SR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Role of leuprolide acetate depot in hysteroscopic surgery: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone. Analogue depot therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

"Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Depot leuprolide acetate dosage for sexual precocity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Two-year results of treatment with depot leuprolide acetate for central precocious puberty

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Long-acting delivery systems for narcotic antagonists. 1

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

The influence of polymer glass transition temperature and molecular weight on drug release from tablets containing poly(DL-lactic acid)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

New method for analysis of biodegradable polyesters by high-performance liquid chromatography after alkali hydrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Histologic comparison of polylactic and polyglycolic acid sutures

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Biodegradation of and tissue reaction to poly(DL-lactide) microcapsules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Tissue response to biodegradable injectable microcapsules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Controlled Release of a Luteinizing Hormone-Releasing Hormone Analogue from Poly(d,l-lactide—co-glycolide) Microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

A New Long-Acting Injectable Microcapsule System for the Administration of Progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation technique. II. Some process parameters influencing the preparation and properties of microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Entrapment of proteins in poly(L-lactide) microspheres using reversed micelle solvent evaporation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Stabilization of tetanus toxoid in poly(DL-lactic-co-glycolic acid) microspheres for the controlled release of antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

A month-long effect from a single injection of microencapsulated human growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Stabilization of nerve growth factor in controlled release polymers and in tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Effect of particle size on the in vitro and in vivo degradation rates of poly(DL-lactide-co-glycolide) microcapsules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Preparation and in vitro degradation properties of polylactide microcapsules.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Mechanism of hydrolytic degradation of poly(L-lactide) microcapsules: effects of pH, ionic strength and buffer concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation method. III. Morphology of the microspheres during dissolution studies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

In vitro and in vivo evaluation of thyrotrophin releasing hormone release from copoly(dl-lactic/glycolic acid) microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

A radioimmunoassay for a highly active luteinizing hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

The effect of a luteinizing hormone releasing hormone (LRH) agonist (Wy-40,972), levonorgestrel, danazol and ovariectomy on experimental endometriosis in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2897%2900050-1

7 January 2021

10.1016/S0169-409X(97)00050-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837564%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference